SP-563

About Stamford Pharmaceuticals

Stamford Pharmaceuticals is a private, clinical-stage biotech advancing an oncolytic adenovirus platform, SP-002, primarily for skin cancers like Basal Cell Carcinoma (BCC). The company has reported positive Phase 2 results and is planning a Phase 3 trial for 2025/26, while also exploring its vector-drug conjugate platform for pancreatic and bladder cancers. Led by a small, experienced team with industry and investment backgrounds, Stamford is positioned in the growing cell and gene therapy sector but faces significant development and competitive risks common to early-stage oncology biotechs.

Therapeutic Areas

Other Non-Muscle Invasive Bladder Cancer Drugs